Results 221 to 230 of about 11,227,343 (266)

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

open access: yesMolecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq   +8 more
wiley   +1 more source

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

open access: yesMolecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park   +6 more
wiley   +1 more source

Growing public interest and regional disparities of cardiorenal syndrome in the United States. [PDF]

open access: yesFront Digit Health
Schlesinger RP   +4 more
europepmc   +1 more source

Perspectives of consumer involvement in pre-clinical musculoskeletal research: a cross-sectional survey of consumers and community members. [PDF]

open access: yesRheumatol Adv Pract
Ross MH   +9 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy